Zymoplex Capsule generic Price of zymoplex capsule. Uses, Dosage, Side effects
Dosages greater than 20 mg per day should be given in divided doses (morning and evening). Tamoxifen should not be used in patients with a known allergy tothe drug or any component in its formulation or concomitantly with warfarin. For patients taking tamoxifen for breast cancer risk reduction at high risk for breast cancer or ductal carcinoma in situ, it should be avoided if the patient has a history of deep vein thrombosis (DVT) or pulmonary buy steroids for bodybuilding embolism (PE). In patients that have been diagnosed with breast cancer, the benefits outweigh the risks, but it should still be used with caution in patients with a history of thromboembolic events. These results show that, on average, in high-risk women who still had their uterus, Zymoplex tablets doubled the chance of getting endometrial cancer from 1 in 1,000 to 2 in 1,000, and it increased the chance of getting uterine sarcoma.
- In the NSABP P-1 trial, 6 women on tamoxifen and 2 on placebo experienced grade 3 to 4 drops in platelet counts.
- When tamoxifen is coadministered with chemotherapy, there may be a further increase in the incidence of thromboembolic effects.
- If hypercalcemia does occur, appropriate measures should be taken and, if severe, tamoxifen should be discontinued.
Zymoplex tablets are indicated for the treatment of node-positive breast cancer in women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. In some tamoxifen adjuvant studies, most of the benefit to date has been in the subgroup with four or more positive axillary nodes. Altamofen Tamoxifen Citrate helps to reduce the risk of recurrence of breast cancer and improve the survival rate of patients. It works by blocking the effects of estrogen hormone in the breast tissue, preventing the cancer cells from growing and spreading.
Tamoxifen « Ebewe » (AUSTRIA)
It is important to tell a doctor if any of these side effects persist or become severe. More serious side effects, although rare, can include blood clots, stroke, and endometrial (uterine) cancer. The recommended dose is 20 mg to 40 mg per day, depending on the patient’s clinical response and tolerance. Altamofen Tamoxifen Citrate is also used as a preventive medicine for women who are at high risk of developing breast cancer.
Continued clinical studies have resulted in further information which better indicates the incidence of adverse reactions with tamoxifen as compared to placebo. Variations in the karyopyknotic index on vaginal smears and various degrees of estrogen effect on Pap smears have been infrequently seen in postmenopausal patients given tamoxifen. In the NSABP P-1 trial, 6 women on tamoxifen and 2 on placebo experienced grade 3 to 4 drops in platelet counts.
Key Benefits of Tamoxifen
During the ATAC trial, more patients receiving anastrozole were reported to have an elevated serum cholesterol compared to patients receiving Zymoplex (tamoxifen citrate) (9% versus 3.5%, respectively). Zymoplex (tamoxifen citrate) may cause fetal harm when administered to a pregnant woman. Women should be advised not to become pregnant while taking Zymoplex (tamoxifen citrate) or within 2 months of discontinuing Zymoplex (tamoxifen citrate) and should use barrier or nonhormonal contraceptive measures if sexually active. Effects on reproductive functions are expected from the antiestrogenic properties of the drug. In reproductive studies in rats at dose levels equal to or below the human dose, nonteratogenic developmental skeletal changes were seen and were found reversible.
- Altamofen Tamoxifen Citrate is a widely used medication for the treatment and prevention of breast cancer.
- In patients with significant thrombocytopenia, rare hemorrhagic episodes have occurred, but it is uncertain if these episodes are due to Zymoplex (tamoxifen citrate) therapy.
- You can also measure the correct dosage with the dropper and mix it in 1 ounce of cool water, infant formula, or juice.
- Tamoxifen also has been found to increase levels of micronucleus formation in vitro in human lymphoblastoid cell line (MCL-5).
There are no data to suggest that routine endometrial sampling in asymptomatic women taking Zymoplex (tamoxifen citrate) to reduce the incidence of breast cancer would be beneficial. Any patient receiving or having previously received Zymoplex who reports abnormal gynaecological symptoms, especially vaginal bleeding, or who presents with menstrual irregularities, vaginal discharge and symptoms such as pelvic pain or pressure should be promptly investigated. On the NSABP P-1 trial, hot flashes of any severity occurred in 68% of women on placebo and in 80% of women on tamoxifen. Severe hot flashes occurred in 28% of women on placebo and 45% of women on tamoxifen. Vaginal discharge occurred in 35% and 55% of women on placebo and tamoxifen respectively; and was severe in 4.5% and 12.3% respectively. At a median follow-up of 33 months, the combination of anastrozole and tamoxifen did not demonstrate any efficacy benefit when compared to tamoxifen therapy given alone in all patients as well as in the hormone receptor positive subpopulation.
In other adjuvant studies, Toronto and Tamoxifen Adjuvant Trial Organization (NATO), women received either tamoxifen or no therapy. In the Toronto study, hot flashes were observed in 29% of patients for tamoxifen vs. 1% in the untreated group. In the NATO trial, hot flashes and vaginal bleeding were reported in 2.8% and 2.0% of women, respectively, for tamoxifen vs. 0.2% for each in the untreated group.
Leukopenia has been observed, sometimes in association with anemia and/or thrombocytopenia. There have been rare reports of neutropenia and pancytopenia in patients receiving Zymoplex (tamoxifen citrate) ; this can sometimes be severe. As with other additive hormonal therapy (estrogens and androgens), hypercalcemia has been reported in some breast cancer patients with bone metastases within a few weeks of starting treatment with Zymoplex (tamoxifen citrate). If hypercalcemia does occur, appropriate measures should be taken and, if severe, Zymoplex (tamoxifen citrate) should be discontinued.
Rifampin induced the metabolism of tamoxifen and significantly reduced the plasma concentrations of tamoxifen in 10 patients. Aminoglutethimide reduces tamoxifen and N-desmethyl tamoxifen plasma concentrations. Medroxyprogesterone reduces plasma concentrations of N-desmethyl, but not tamoxifen.
What other drugs will affect Zymoplex?
The long-term effects of Zymoplex (tamoxifen citrate) therapy for girls have not been established. In adults treated with Zymoplex (tamoxifen citrate) , an increase in incidence of uterine malignancies, stroke and pulmonary embolism has been noted (see BOXED WARNING, and CLINICAL PHARMACOLOGY-Clinical Studies-McCune-Albright Syndrome subsection). In the NSABP P-1 trial, 6 women on Zymoplex (tamoxifen citrate) and 2 on placebo experienced grade 3-4 drops in platelet counts ( ≤ 50,000/mm³).